US Branded Generics Market was valued at $19.1 billion in 2022, is poised to witness a Healthy Growth of ~9-10% by 2027

Branded generics are generic drugs which are given a proprietary market name. It can be developed by a generic drug company or by the original manufacturer and can be promoted in the market after the patent expiry of the original drug. They are sold by using a brand name instead of a chemical name. An abbreviated new drug application (ANDA) is submitted to the regulatory body for marketing and promoting branded generics and it should be therapeutically equivalent to the original drug for which the patent is expired.

Multiple Benefits Offered by Branded Generics Drives its Adoption in the U.S Branded Generics Market

Due to the numerous benefits offered by branded generics, their adoption is anticipated to grow rapidly in United States. Following are the benefits:-

• They are sold as alternative to brand-name drugs and are comparatively cheap.
• For combination drugs, it is quite tough to remember their generic names. Branded generics can be easily remembered.
• They attract many and potential consumers who only prefer branded drugs.
• They provide quality assurance from established and leading companies.

“Branded generics contain only a low percentage of total generic prescriptions in United States but they are more profitable than unbranded generics.”-Tier I Branded Generic Manufacturer, United States

Foray of India Market Players Adds A Competitive Intensity to the US Branded Generics Market

The market share of the Indian players in the US branded generics market is set to grow in the next five years due to the following factors:

o??High R&D Spend: Leading Indian players continue to invest heavily in their R&D activities. Key Indian players have increased their R&D budgets over the last few years, thus indicating a good launch pipeline.

o??Entry of New Indian players: The US market continues to see the entry of new Indian players every year and these companies are poised to further drive the market share of the Indian players in overall ANDA approvals.

o??CDMO Entry: Few Indian CDMOs are also planning to enter the US market.

o??Emphasis of Indian market players is on complex generics where competition is comparatively less and they can launch their products early.

Unmet Patient Requirements Fuels the Growth of the US Branded Generics Market

The unmet patient requirements in the cardiovascular, gastroenterology, diabetology, oncology, pain management and dermatology therapeutic segments is driving the growth of the US branded generics market. Other application segments which are witnessing a rising demand are women’s health, neurology, ophthalmology, respiratory, hormonal, anti-psychotic, and infectious diseases.

Competitive Landscape Analysis: US Branded Generics Market

The U.S branded generics market is marked by the presence of top market players such as Teva Pharmaceuticals , Mylan , Sandoz , SUN PHARMA , Hikma Pharmaceuticals , among others.

Growth Strategies Adopted by the Leading Market Players to Establish Their Foothold in the US Branded Generics Market

The established industry players operating in the U.S branded generics market have adopted the growth strategies such as acquisitions, collaborations, advancements, developments and partnerships to garner a larger market share. For instance,

• In November 2021, ANI Pharmaceuticals completed the takeover of Novitium Pharma, thus rapidly enhancing its R&D capabilities and scale of generics and CDMO businesses.

The outlook of the U.S branded generics market looks very promising due to the patent expiry of many drugs, rapid growth of Indian companies, comparatively more profitability as compared to unbranded generics and an unmet patient needs across many other therapeutic areas. However, high costs compared to unbranded generics is one of the prime factor which is likely to affect the market growth.

Get Detailed Insights on US Branded Generics Market Report with TOC @ https://meditechinsights.com/us-branded-generics-market/

#brandedgenerics #generics #chronicdiseases #drugs #patentexpiry #genericdrugs #genericmedicines #generic #drugsafety #drugdiscovery #drugdevelopment #drugdelivery #drugtesting #drugmanufacturing #brandeddrugs #cardiovascular #gastroenterology #diabetology #oncology #painmanagement #dermatology #therapeutic #womenhealth #neurology #ophthalmology #respiratory #hormonal #antipsychotic #infectiousdiseases #womenhealthcare #healthcare #pharmaceutical #medicalcare #marketresearch #healthcareconsulting